Ursosan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursosan

Quick Facts About Ursosan

Property Description
Active Ingredient Ursodeoxycholic acid (UDCA) / Ursodiol
Form Oral Capsule or Tablet
Pharmacological Class Bile Acid Derivative
General Purpose Managing bile composition and liver cell protection
Origin Synthetic, based on a natural bile acid

What Type of Medicine is Ursosan?

Ursosan is a brand of prescription medicine that belongs to the pharmacological class of bile acid derivatives, used to manage certain liver and gallbladder conditions. It is a targeted therapeutic agent regulated by health authorities, distinguishing it from non-pharmaceutical supplements. UDCA is a bile acid recognized for the treatment of specific hepatobiliary conditions.

The primary active ingredient is officially named ursodeoxycholic acid (UDCA), or ursodiol. This compound is clinically recognized for its action on bile composition and flow, making it a critical part of treatment where bile movement is impaired or cholesterol levels in the bile are imbalanced.

Is Ursosan a Natural or Synthetic Compound?

The active ingredient, UDCA, is chemically identical to a naturally occurring bile acid present in small amounts in human bile, but the medicine is produced through a synthetic manufacturing process. While the compound was first characterized from the bile of bears (Ursus)—hence the name—the pharmaceutical version is synthesized in a lab to guarantee purity and a specific, consistent concentration. Ursosan is administered orally, typically in the form of a capsule or tablet.

What is the General Goal of Ursosan Treatment?

The general goal of treatment with Ursosan is to improve overall bile health and function within the liver and gallbladder system. The treatment works by altering the cholesterol saturation of bile. This means the medicine helps prevent the formation of solid material in the bile system by changing its chemical makeup. By increasing the concentration of the gentler UDCA, the therapy helps protect the delicate cells lining the bile ducts and normalizes the environment necessary for efficient biliary function.

Regulatory References

  1. National Institutes of Health (NIH)
  2. NIH StatPearls

What side effects are possible with Ursosan?

Possible Side Effects and Safety Information

The safety profile of Ursodeoxycholic acid (Ursosan) is officially documented by regulatory authorities, which classify adverse reactions based on frequency and the body system affected. This classification allows for a neutral presentation of the observed effects, strictly following the structure found in regulatory documents like the Summary of Product Characteristics (SmPC) and FDA labeling.


Documented Adverse Reactions and Frequency

The most frequently reported side effects are primarily related to the Gastrointestinal Disorders system-organ class:

  • Common (affecting 1 to 10 out of 100 patients): Diarrhea and the passing of pasty stools.
  • Uncommon (affecting 1 to 10 out of 1,000 patients): Urticaria (hives) and Pruritus (itching) have been documented under Skin and Subcutaneous Tissue Disorders.

Serious Safety Considerations

In the Hepatobiliary Disorders system, specific, clinically significant observations are officially categorized as Very Rare (affecting fewer than 1 in 10,000 patients):

  • Calcification of existing gallstones has been observed during treatment.
  • Decompensation of hepatic cirrhosis has been reported in patients with advanced Primary Biliary Cholangitis (PBC). Official labeling notes that this effect has been partially reversible upon discontinuation of the medicine.

Safety Restrictions and Limitations

The official labeling defines specific constraints where the medicine is not to be used, which include acute inflammation of the gallbladder or biliary tract, obstruction of the biliary tract (such as the common bile duct), the presence of radiologically visible calcified gallstones, or impaired contractility of the gallbladder. For women who are pregnant or breastfeeding, regulatory documents require a formal assessment of benefits versus risks by a healthcare professional.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based strictly on official governmental regulatory documents for Ursosan (ursodeoxycholic acid).

Documented Overdose Profile

Official regulatory data indicates a limited number of reports concerning accidental or intentional overdosage in humans. Consequently, the overdose profile is primarily drawn from known effects at high doses.

Overdose Aspect Official Regulatory Statement
Expected Manifestation The most frequently documented clinical sign of overdosage is diarrhea; serious adverse effects are not commonly documented in the limited human reports.
Antidote No specific chemical antidote is mentioned in the official regulatory documentation for ursodeoxycholic acid.
Population-Specific Risks The regulatory overdose section does not specify separate risk profiles or considerations for pediatric or geriatric patients.

Management and Seeking Urgent Care

In the event of an overdose, management is generally symptomatic and supportive. Treatment should specifically address the clinical manifestation of diarrhea.

The official labels do not specify explicit criteria or timeframes for seeking urgent medical help due to the lack of severe acute human toxicity reports. However, any suspected overdosage or signs of escalating symptoms requires immediate professional medical evaluation, consistent with general emergency procedures.

Therapeutic Uses of Ursosan

What Ursosan Treats: Main Uses and Benefits

Ursosan is applied across domains where additional symptomatic support is needed and is relevant for easing symptoms related to organ-specific functional stress and physiological comfort.

The medicine is used for the treatment of patients with primary biliary cholangitis (PBC). Its therapeutic application focuses on conditions involving episodic or fluctuating manifestations, symptoms linked to organ-specific functional stress, and symptoms related to inflammatory or irritative states.


Easing Symptoms of Primary Biliary Cholangitis (PBC)

Ursosan is commonly used for Primary Biliary Cholangitis, an immune-mediated liver condition. It is applied in situations involving certain distressing symptoms. The medication helps address symptom clusters that may become intense or disruptive, and generally provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Support for Symptom Management

The drug is commonly used across conditions presenting with acute episodes where symptoms are linked to organ-specific functional stress. It is applied across domains where additional symptomatic support is needed, offering relief that helps maintain a sense of stability when symptoms are more noticeable. It is also considered relevant in contexts marked by increased discomfort resulting from bile reflux gastritis, where it assists with maintaining functional stability.


Quick Fact: Relief for Functional Strain

Ursosan is used for managing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Ursosan (Ursodeoxycholic Acid)

Official regulatory documents strictly define the eligibility criteria for Ursosan (ursodeoxycholic acid) use, focusing primarily on the patient's existing biliary condition and physiological status.

Absolute Contraindications (Must Not Use): Ursosan is formally contraindicated and must not be used in the following situations:

  • Biliary Pathology: Patients experiencing acute inflammation of the gallbladder or bile ducts, or complete biliary tract obstruction. Contraindication also applies to those with impaired gallbladder contractility.
  • Hepatic Status: Individuals with decompensated hepatic cirrhosis (severe liver impairment) are excluded.
  • Gallstone Type: The drug is ineffective and prohibited for treating calcified gallstones; it is only suitable for non-calcified cholesterol stones.

Population Restrictions:

  • Pregnancy Status: Use is contraindicated during the first trimester of pregnancy. Women of childbearing potential must use reliable contraception throughout treatment. Use is not recommended during breastfeeding.
  • Age-Group Eligibility: While approved for adults, eligibility for the pediatric population is restricted to children aged 6 to 18 years for specific hepatobiliary disorders linked to cystic fibrosis. Efficacy is generally not established for other indications in younger children.
  • Monitoring: Treatment requires mandatory, regular monitoring of liver function tests for all patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Ursosan (Ursodeoxycholic Acid) are primarily documented around reducing its absorption or efficacy, and its potential to alter the exposure of certain co-administered drugs.

Pharmacokinetic Interactions and Timing

Interacting Product Category Effect on Ursosan or Co-drug Interaction Constraint
Bile Acid Sequestrants (e.g., Cholestyramine) Significantly reduces Ursosan absorption. Must be taken at least 2 hours before or after Ursosan.
Aluminum-Based Antacids Reduces Ursosan absorption via binding. Must be taken at least 2 hours before or after Ursosan.
Immunosuppressants (e.g., Cyclosporine) Ursosan may reduce exposure of the co-drug (via possible CYP3A4 induction). Co-drug concentration must be monitored.
Calcium Channel Blockers (e.g., Nitrendipine) Ursosan may reduce exposure of the co-drug. Co-drug dosage may require adjustment.

Pharmacodynamic Interactions

Certain medications are documented to counteract the therapeutic effects of Ursosan, as they increase the amount of cholesterol secreted into the bile, working against the drug's purpose.

  • Estrogens and Oral Contraceptives
  • Lipid-Lowering Agents (e.g., Clofibrate)

These counteracting agents are generally not recommended for co-administration. If co-administration is necessary for absorption-reducing agents, strict adherence to the required timing separation is essential to maintain the efficacy of Ursosan.

Mechanism of Action

How Ursosan Works: The Pharmacodynamic Mechanism

Ursosan's active component, Ursodeoxycholic acid (UDCA), exerts its effect through multiple and coordinated pharmacodynamic mechanisms to modulate bile acid composition and flow and confer cellular stabilization.


Modulating Bile Composition and Litholytic Action

This mechanism involves UDCA's action as a displacement agent within the enterohepatic circulation to replace toxic bile acids with the more hydrophilic UDCA. It also acts as an inhibitor of cholesterol absorption and hepatic cholesterol secretion. This modifies the cholesterol saturation index of bile, which is essential for facilitating the transition from crystalline to soluble cholesterol state and reducing the cholesterol saturation index.


Cellular Stabilization and Cytoprotection

This domain focuses on structural integrity at the subcellular level. UDCA integrates into the hepatocyte and cholangiocyte plasma membranes and mitochondrial membranes, stabilizing them against damage. It functions as an inhibitor of the apoptotic pathway and helps attenuate Reactive Oxygen Species (ROS) generation. This maintains the structural integrity and limits apoptosis and necrosis of liver cells.


Enhancing Bile Flow and Immunomodulation

UDCA achieves a choleretic effect by stimulating the function of ion transporters, such as the chloride-bicarbonate exchanger ( AE2), which increases the secretion of HCO3^--rich fluid. Concurrently, UDCA acts as a modulator by suppressing inflammatory signaling pathways ( NF-kappa B) within the liver. This activity increases bile flow and volume while suppressing inflammatory signaling pathways and related immune cell activity within the biliary system.

Dosage and Administration Information

How Ursosan is Used: General Administration Guidelines

Ursosan, which contains ursodeoxycholic acid (UDCA), is administered via the oral route using capsules, tablets, or, in some regions, an oral suspension. Dosing instructions are typically based on the patient's body weight and the specific condition being addressed.

Administration Scope

Instruction Component General Guideline
Dosing Regimen Typically weight-based, ranging from 8–15 mg/kg of body weight per day, depending on the indication.
Frequency and Timing The total daily dose is administered in two to four divided doses with food. The final or largest dose of the day is often directed to be taken at bedtime.
Preparation Scored tablets, such as the 500 mg strength, can be broken to facilitate achieving the calculated dose, but must be swallowed whole with water and not chewed.
Pediatric Use Dosing for children, such as those with cystic fibrosis-associated hepatobiliary disorders, is body weight-related (e.g., 20 mg/kg/day) and administered in divided doses.
Missed Dose If a dose is missed, it should be taken as soon as it is remembered, unless it is near the time for the next scheduled dose, in which case the missed dose is skipped.

Course Duration

Treatment duration varies: for conditions like Primary Biliary Cholangitis, therapy is typically planned for the long term. For uses such as gallstone dissolution, the course may last from six months up to two years and is often continued for an additional three to four months after complete stone dissolution has been confirmed by follow-up examinations.

General Step Sequence:

  • The total daily dose is calculated according to the patient's body weight.
  • This dose is divided into several administrations throughout the day.
  • The medicine is ingested orally with food, ensuring the last dose is typically taken at bedtime.

This protocol ensures a standardized method of administration across different clinical usage contexts.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ursosan

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research for Primary Biliary Cholangitis (PBC), a condition marked by functional limitations and systemic imbalance, has primarily relied on large-scale Randomized Controlled Trials (RCTs) and extensive observational studies. These studies were evaluated in adult patient populations. The core outcomes studies monitored included long-term clinical endpoints, such as the need for a liver transplant or survival, alongside changes in key liver health indicators like Alkaline Phosphatase (ALP) and Bilirubin.

The findings from these studies indicate patterns related to the observed populations. Research describes patterns related to changes in measurements of liver function markers in a significant portion of patients over the study period. Data from long-term observational studies show patterns related to outcomes monitored in research, such as transplant-free survival, particularly in the group of patients who had an early change in their biochemical markers.

Research on Cholesterol Gallstone Dissolution

Controlled clinical trials focused on the use of this agent in patients with specific conditions: the presence of cholesterol-rich gallstones (radiolucent stones) and a functioning gallbladder. The primary research goal was evaluated in studies exploring the dissolution of these stones, measured by repeated imaging over time. Studies reported patterns related to changes in the bile's cholesterol saturation, indicating that dissolution is generally a long-term process, with observation periods often spanning many months or even years.

Research limitation frames apply here, as studies describe that dissolution was not observed for stones that contain significant amounts of calcium (calcified stones) or if the gallbladder’s function is impaired. Studies focusing on short-term symptom changes related to gallstone discomfort are limited.

What is Still Uncertain About Ursosan Research

Across all indications, several limitations and gaps in the evidence base exist. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. A common theme is that there is limited information for long-term outcomes beyond the duration of the structured trials. For the PBC population, certainty remains low regarding the long-term clinical progression for the subgroup of patients who showed less distinct changes in laboratory tests.

Frequently Asked Questions (FAQ)

Common questions about Ursosan (FAQ)

Q: Does Ursosan help with digestion in general?

According to the official product information, Ursosan's active component, ursodeoxycholic acid, works by modulating the flow and composition of bile. Bile is a substance naturally produced by the liver, and its function involves assisting with the breakdown and absorption of fats during the digestive process.

Q: What does the research say about Ursosan's potential for primary biliary cirrhosis (PBC)?

Official regulatory documentation states that Ursosan is indicated for the treatment of Primary Biliary Cholangitis (PBC). Research evidence indicates that therapy is often planned for the long term when managing this specific chronic liver condition.

Q: Do studies support Ursosan's role in cystic fibrosis-related liver disease?

Official prescribing guidelines mention specific, weight-related dosing regimens for use in children who have cystic fibrosis-associated hepatobiliary disorders. This indicates that regulatory bodies recognize its use for this condition in certain pediatric populations, a practice supported by studies.

Q: What is the main goal of treatment with Ursosan?

According to the primary indications listed in official sources, the main goals of treatment with Ursosan are the dissolution of certain types of cholesterol gallstones and the management of Primary Biliary Cholangitis (PBC).

Q: How quickly do people usually notice any effect from Ursosan?

For chronic conditions, such as gallstones or liver disease, the full therapeutic effect of Ursosan can take many months to observe. However, some sources suggest the medicine's activity begins in the body after about three days, though the patient typically may not notice any immediate, visible changes.

Q: Is it normal to feel a change in bowel movements when starting Ursosan?

Changes in bowel movements, such as diarrhea or pasty stools, are reported in official product documents as common or very common undesirable effects during therapy. More details about the frequency of side effects are available in the dedicated section on possible side effects.

Q: What are the most commonly reported mild side effects of Ursosan?

Official regulatory sources list common undesirable effects, which may include mild symptoms such as headache, abdominal pain, diarrhea, and nausea. A complete list of all reported side effects, including less common ones, is included in the dedicated section on possible side effects.

Q: Are there any long-term safety concerns described for Ursosan?

Regulatory documents include warnings that, in very rare cases during treatment for advanced Primary Biliary Cholangitis, a worsening of liver cirrhosis (known as decompensation) has been observed. This condition typically improved after discontinuing the drug. Regulatory information highlights the importance of regular liver function monitoring during long-term use.

Q: Can Ursosan cause a skin rash?

Yes, skin reactions, including generalized skin rash and urticaria (hives), are described in official documents as rare to very rare undesirable effects. More detail on this undesirable effect is included in the separate safety and side effects section.

Q: Is Ursosan a prescription-only medicine?

According to regulatory documentation, Ursosan (ursodeoxycholic acid) is a prescription-only medicine. This means it requires a prescription from a licensed healthcare provider.

Q: Are there any known interactions between Ursosan and blood thinners?

Official product information notes that Ursosan may affect the concentration of certain co-administered drugs. For patients taking blood thinners (anticoagulants), regulatory documents state that their coagulation status should typically be monitored by a physician during therapy.

Q: Is there a generic version of Ursosan available?

Yes, the active ingredient in Ursosan, which is ursodeoxycholic acid (UDCA), is widely available in generic form. It is often marketed under its chemical name, Ursodiol or Ursodeoxycholic Acid, in various regions globally.

Q: Does Ursosan affect fertility in men or women?

Official documents advise women of childbearing potential receiving treatment for gallstone dissolution to use effective non-hormonal contraception. This is because hormonal oral contraceptives may counteract the effect of the drug. The regulatory information does not clearly define other specific effects on fertility.

Q: Does Ursosan have a bitter taste if the capsule opens?

Patient instructions for certain dosage forms advise against chewing or allowing split tablets to dissolve in the mouth. This is typically done to maintain the intended method of administration and because the medication can have a bitter taste.

Q: What types of liver enzyme changes might be monitored while on Ursosan?

Regulatory documents state that during treatment, healthcare providers typically monitor liver function tests. This testing involves measuring serum levels of transaminases (ALT/AST) and alkaline phosphatase to track the body’s response to the medicine.

Q: Can Ursosan be used to prevent gallstones?

Yes, official drug documents indicate that Ursosan is approved for the prevention of gallstone formation. This specific use is noted for patients who are undergoing rapid weight loss, such as after bariatric surgery.

Q: Are there any warnings about driving or operating machinery while using Ursosan?

Official regulatory information directly addresses this, stating that Ursosan is not known to have any influence on a person’s ability to drive or safely use heavy machinery.

Q: What is the official safety classification of Ursosan during pregnancy?

The official safety classification varies by region. For instance, in the European Union, the product is generally not recommended for use during pregnancy unless clearly necessary. The Australian government places the drug in the TGA pregnancy category B3.

Q: Does taking Ursosan require regular blood tests?

Regulatory documents state that liver function tests are typically checked by a healthcare provider before beginning treatment. These blood tests should then be repeated regularly, particularly during the first few months of therapy.

Q: What if I accidentally took two doses of Ursosan?

Official documents state that diarrhea is the likely consequence of taking a temporary overdose. Regulatory information mentions that dose reduction is typically used to manage this effect.

Q: What are the main contraindications listed for Ursosan?

Main contraindications, or situations where the drug should not be used, are listed in official documents. These include acute inflammation of the gallbladder or biliary tract, a blockage of the biliary tract, and the presence of gallstones that have become calcified (radio-opaque).

Q: Does Ursosan need to be stored in the refrigerator?

The capsules or tablets generally do not require special storage conditions, such as refrigeration. The official guidelines recommend that the product should be stored at room temperature, protected from light and moisture.

Q: Is there a link between Ursosan and increased risk of infection?

Official regulatory lists of side effects commonly include certain symptoms that may resemble infection, such as upper respiratory tract infections and common cold symptoms. This is listed as an undesirable effect, the frequency of which is detailed in the safety information.

How should Ursosan be stored and disposed of?

Storage and Disposal Requirements for Ursosan

Official regulatory information strictly defines the proper storage and disposal of this medicine, focusing on temperature control, child safety, and packaging integrity.

Storage Conditions

  • Temperature and Environment: Store the medicine in a cool, dry place and do not store above 25 C. Protection from heat and damp is required. Do not leave the product in the car, bathroom, or near a sink.
  • Child Safety: It is mandatory to keep the medicine out of the sight and reach of children, ideally in a secure, locked cupboard.
  • Packaging: Keep the capsules or tablets in the original pack (e.g., blister pack) to maintain stability. Do not use the medicine if the packaging is damaged or past the expiry date.

Disposal Instructions

  • Unused Medicine: Any unused or expired Ursosan must be returned to a pharmacy for safe disposal.
  • Environmental: The product must not be disposed of via household waste, sewers, or drains, and disposal must align with local, regional, and national environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursosan found in:

A-Z Index: